Comparison of Drug Resistance Mutations and Their Interpretation in Patients Infected with Non-B HIV-1 Variants and Matched Patients Infected with HIV-1 Subtype B

Journal of Acquired Immune Deficiency Syndromes

Volumn 35, Issue 4, 2004, Pages 329-336

  Montes, Brigitte ^a   Vergne, Laurence ^b   Peeters, Martine ^b   Reynes, Jacques ^a   Delaporte, Eric ^a,b   Segondy, Michel ^a,c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c HÔPITAL SAINT ELOI   (France)

Author keywords

HIV 1; Mutations; Non B variants; Protease; Resistance; Reverse transcriptase

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ALGORITHM; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; STRAIN DIFFERENCE; VIRUS GENE;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MIDDLE AGED; MUTATION; VARIATION (GENETICS);

EID: 1542618485     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200404010-00001     Document Type: Article

References (36)

1. Tatt IA, Barlow KL, Nicoll A, et al. The public health significance of HIV-1 subtypes. AIDS. 2001;15(Suppl 5):S59-S71.
2. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA. 2000;283:2417-2426.
3. The EuroGuidelines Group for HIV resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS. 2001;15:309-320.
4. Apetrei C, Descamps D, Collin G, et al. Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility. J Virol. 1998;72:3534-3538.
5. Cornelissen M, van den Burg R, Zorgdrager F, et al. pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D. J Virol. 1997;71:6348-6358.
6. Descamps D, Apetrei C, Collin G, et al. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. AIDS. 1998;12:1109-1111.
7. Pieniazek D, Rayfield M, Hu DJ, et al. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. AIDS. 2000;14:1489-1495.
8. Vergne L, Peeters M, Mpoudi-Ngole E, et al. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol. 2000;38:3919-3925.
9. Deroo S, Robert I, Fontaine E, et al. HIV-1 subtypes in Luxembourg, 1983-2000. AIDS. 2002;16:2461-2467.
10. Palmer S, Alaeus A, Albert J, et al. Drug susceptibility of subtypes A, B, C, D, and E human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses. 1998;14:157-162.
11. Frater AJ, Beardall A, Ariyoshi K, et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS. 2001;15:1493-1502.
12. Pillay D, Walker AS, Gibb DM, et al. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect Dis. 2002;186:617-625.
13. Alexander CS, Montessori V, Wynhoven B, et al. Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia. Antivir Ther. 2002;7:31-35.
14. Easterbrook PJ, Smith M, Mullen J, et al. Relationship between HIV-1 viral subtype, disease progression, and response to antiretroviral therapy [abstract 907]. Presented at the 10th Conference on Retroviruses and Opportunistic Infection, Boston, February 2003.
15. Pasquier C, Millot N, Njouom R, et al. HIV-1 subtyping using phylogenetic analysis of pol gene sequences. J Virol Methods. 2001;94:45-54.
16. Yahi N, Fantini J, Tourres C, et al. Use of drug resistance sequence data for the systematic detection of non-B human immunodeficiency virus type 1 (HIV-1) subtypes: how to create a sentinel site for monitoring the genetic diversity of HIV-1 at a country scale. J Infect Dis. 2001;183:1311-1317.
17. Montes B, Segondy M. Prevalence of the mutational pattern E44D/A and/or V118I in the reverse transcriptase (RT) gene of HIV-1 in relation to treatment with nucleoside analogue RT inhibitors. J Med Virol. 2002;66:299-303.
18. Thompson JD, Higgins DG, Gibson TJ, et al. CLUSTAL W. Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22:4673-4680.
19. Touré-Kane C, Montavon C, Faye MA, et al. Identification of all HIV type 1 group M subtypes in Senegal, a country with low and stable seroprevalence. AIDS Res Hum Retroviruses. 2000;16:603-609.
20. Shafer RW, Chuang TK, Hsu P, et al. Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe. AIDS Res Hum Retroviruses. 1999;15:65-69.
21. Perez-Alvarez L, Cuevas MT, Villahermosa ML, et al. Prevalence of drug resistance mutations in B, non-B subtypes, and recombinant forms of human immunodeficiency virus type 1 in infected individuals in Spain (Galicia). J Hum Virol. 2001;4:35-38.
22. Cane PA, de Ruiter A, Rice P, et al. Resistance-associated mutations in the human immunodeficiency virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom. J Clin Microbiol. 2001;39:2652-2654.
23. Fleury H, Recordon-Pinson P, Caumont A, et al. HIV type 1 diversity in France, 1999-2001: molecular characterization of non-B HIV type 1 subtypes and potential impact on susceptibility to antiretroviral drugs. AIDS Res Hum Retroviruses. 2003;19:41-47.
24. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus population in persons treated with lamivudine (3TC). J. Infect Dis. 1995;171:1411-1419.
25. Deeks SG. International perspective on antiretroviral resistance. Non-nucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr. 2001;26(Suppl 1):S25-S33.
26. Masquelier B, Peytavin G, Leport C, et al. Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the Aprovir study. J Infect Dis. 2002;186:1503-1507.
27. Yahi N, Tamalet C, Tourres C, et al. Mutation L210W of HIV-1 reverse transcriptase in patients receiving combination therapy. Incidence, association with other mutations, and effects on the structure of mutated reverse transcriptase. J Biomed Sci. 2000;7:507-513.
28. Wainberg MA, White AJ. Current insights into reverse transcriptase inhibitor-associated resistance. Antivir Ther. 2001;6:11-19.
29. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS. 2003;17(Suppl):F1-F5.
30. Morris L, Pillay C, Chezzi C, et al. Low frequency of the V106M mutation among HIV-1 subtype C-infected women exposed to nevirapine. AIDS. 2003;17:1698-1700.
31. Holguin A, Alvarez A, Soriano V. High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid. AIDS. 2002;16:1163-1170.
32. Bossi P, Mouroux M, Yvon A, et al. Polymorphism of the human immunodeficiency virus type 1 (HIV-1) protease gene and response of HIV-1-infected patients to a protease inhibitor. J Clin Microbiol. 1999;37:2910-2912.
33. Grossman Z, Vardinon N, Chemtop D, et al. Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B. AIDS. 2001;15:1453-1460.
34. Resch W, Ziermann R, Parkin N, et al. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the gag polyprotein precursor aberrantly. J Virol. 2002;76:8659-8666.
35. Ariyoshi K, Matsuda M, Miura H, et al. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. J Acquir Immune Defic Syndr. 2003;33:336-342.
36. Ravela J, Betts BJ, Brun-Vezinet F, et al. HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquir Immune Defic Syndr. 2003;33:8-14.